A Pioneering Legal Battle Could Reshape Cancer Care Funding and Challenge the Status Quo of Medical Aid Schemes
Imagine being told that essential cancer treatments you need might not be fully covered by your health insurance, despite legal guarantees. And this is precisely the challenge faced by many patients, now entering into a significant legal test that might force health schemes to overhaul their payment policies for critical treatments. But here’s where it gets controversial: should medical schemes be allowed to limit coverage, even for prescribed minimum benefits that are supposed to ensure access to essential healthcare for all?
In the spotlight is Oscar Chalupsky, a 62-year-old former sports hero from Cape Town, who is taking on the country’s largest medical aid provider, Discovery Health, in what could become a landmark case for the rights of cancer patients nationwide. With an estimated three million members, Discovery holds considerable influence over healthcare decisions, and the case has already been submitted to the Council for Medical Schemes, with a crucial decision expected in early 2024.
Chalupsky’s story is inspiring and heartbreaking. A celebrated athlete renowned for his triumphs in surf ski racing and canoe marathons, and a proud representative of South Africa at the 1992 Barcelona Olympics, his life took an unexpected turn in 2019 when he was diagnosed with multiple myeloma—a serious blood cancer impacting plasma cells. This disease is classified under South African law as a "prescribed minimum benefit," meaning all registered medical schemes are legally obliged to cover the costs of essential treatments for such serious conditions, ensuring patients don’t face prohibitive out-of-pocket expenses.
Starting treatment in June 2020, Chalupsky initially responded well, but after three years, his ongoing cancer therapy failed, resulting in recurrent relapses. His doctor prescribed Daratumumab (brand name Darzalex), a targeted drug known to be effective for certain cases of multiple myeloma, especially when previous treatments lose their efficacy or cause significant side effects. Despite the treatment being medically justified, Chalupsky's medical aid approved only half of the cost—leaving him to cover approximately R300,000 through the support of friends and family.
His plight caught the attention of Campaigning for Cancer, an NGO dedicated to helping patients access necessary treatment without losing their financial stability. With their backing, Chalupsky lodged a formal complaint to the Council for Medical Schemes, arguing that his medical treatment was not only justified but should be fully funded in accordance with the law.
Discovery defended its stance, claiming that Chalupsky’s treatment did not follow their recommended treatment plan for his type of cancer, and that jumping straight to Daratumumab without following their sequencing of care wasn’t in line with prescribed minimum benefits. However, the Council disagreed, ruling in favor of Chalupsky: the council emphasized that had his doctor adhered to Discovery’s proposed treatment protocol, the drug might have been ineffective or even harmful. Moreover, the council confirmed that Daratumumab was the appropriate and necessary treatment, and therefore, the scheme should have paid for it entirely.
But controversy escalated when Discovery appealed this decision—not once, but twice. The latest scheduled hearing was postponed to early 2026, resulting in nearly two years of uncertainty for Chalupsky. Meanwhile, the athlete, currently in Shanghai seeking advanced treatment, is footing the bills himself—highlighting the harsh reality faced by many patients who rely on schemes that delay or deny coverage.
Expressing his frustration, Chalupsky has decided to go public, sharing his battle on social media to raise awareness. He recognizes that countless others are in similar or worse situations, often unaware of their rights or unable to secure the treatments they desperately need. "Fighting cancer is exhausting enough," he laments, "and it shouldn’t be made worse by battles with insurance companies that prioritize profit over patient care."
Chalupsky's determination is fueled by his own incredible resilience. Despite being given six months to live early in his diagnosis, he has defied the odds multiple times, even having last rites performed—yet he refuses to surrender. His rallying cry #noretreatnosurrender underscores his unwavering spirit to fight not only his disease but also for the fairness of healthcare access.
His story has ignited passionate online debates, with supporters condemning Discovery’s stance as profit-driven and callous: "Discovery’s priority is profit! They don’t care about patients!" Some have accused the scheme of delaying treatment intentionally, while others question whether the current funding models are sustainable amid rising cancer rates.
In response, Discovery claims that Daratumumab was approved and funded between October 2023 and May 2024, with the scheme covering 75% of the costs and the patient paying just a 25% co-payment—amounting to around R18,500 for part of the treatment. The scheme further states that it has funded over R3 million in Chalupsky’s cancer care, including R1 million specifically for Daratumumab.
However, critics point out an urgent and troubling reality: South Africa faces a looming cancer crisis. A recent study forecasts a sharp increase in cases—from 62,000 in 2019 to an estimated 121,000 by 2030—covering cancers such as breast, cervical, prostate, lung, blood, and childhood cancers. While biological research has advanced, leading to treatments that can significantly prolong life and improve quality of life, these interventions often come with staggering costs.
Lauren Pretorius from Campaigning for Cancer emphasizes that this coming surge underscores the need for health schemes to rethink their funding strategies. She argues that policies must evolve to match the escalating costs of modern cancer therapies—moving away from refusal to pay and shifting the financial burden onto patients. Transparency is crucial, she insists: patients deserve clear explanations about what their premiums cover and why certain treatments are approved or denied.
Pretorius advocates for individualized decision-making, emphasizing that coverage should consider each patient’s unique circumstances and the broader societal benefits of enabling cancer patients to live healthily and productively. She urges schemes to benchmark their policies against the latest international standards, not only to remain relevant but also to uphold ethical commitments to patient care.
As Chalupsky, along with Campaigning for Cancer, continues their fight, they hope this case serves as a wake-up call. It highlights the urgent need for a shift toward smarter, more compassionate healthcare funding—one that balances financial sustainability with the fundamental right to adequate cancer treatment. After all, is sticking to outdated policies more about protecting profits than protecting lives? Understanding this debate is vital, especially as the cancer burden grows—what are your thoughts on whether medical aid schemes can truly serve their members in the face of rising medical costs? Drop your comments and join the conversation.
/file/attachments/orphans/Photo1_132444.jpeg)
